id	sid	tid	token	lemma	pos
dpc-5316	1	1	dermatology	dermatology	NOUN
dpc-5316	1	2	:	:	PUNCT
dpc-5316	1	3	practical	practical	ADJ
dpc-5316	1	4	and	and	CCONJ
dpc-5316	1	5	conceptual	conceptual	ADJ
dpc-5316	1	6	research	research	NOUN
dpc-5316	1	7	letter	letter	NOUN
dpc-5316	2	1	|	|	ADV
dpc-5316	2	2	dermatol	dermatol	ADJ
dpc-5316	2	3	pract	pract	NOUN
dpc-5316	2	4	concept	concept	NOUN
dpc-5316	2	5	.	.	PUNCT
dpc-5316	3	1	2025;15(3):5316	2025;15(3):5316	NUM
dpc-5316	3	2	1	1	NUM
dpc-5316	3	3	efficacy	efficacy	NOUN
dpc-5316	3	4	of	of	ADP
dpc-5316	3	5	bimekizumab	bimekizumab	NOUN
dpc-5316	3	6	in	in	ADP
dpc-5316	3	7	the	the	DET
dpc-5316	3	8	management	management	NOUN
dpc-5316	3	9	of	of	ADP
dpc-5316	3	10	refractory	refractory	NOUN
dpc-5316	3	11	erythrodermic	erythrodermic	ADJ
dpc-5316	3	12	pityriasis	pityriasis	NOUN
dpc-5316	3	13	rubra	rubra	NOUN
dpc-5316	3	14	pilaris	pilaris	NOUN
dpc-5316	3	15	:	:	PUNCT
dpc-5316	3	16	clinical	clinical	ADJ
dpc-5316	3	17	insights	insight	NOUN
dpc-5316	3	18	sofia	sofia	PROPN
dpc-5316	3	19	theotokoglou1	theotokoglou1	PROPN
dpc-5316	3	20	,	,	PUNCT
dpc-5316	3	21	dimitrios	dimitrio	NOUN
dpc-5316	3	22	sgouros1	sgouros1	PROPN
dpc-5316	3	23	,	,	PUNCT
dpc-5316	3	24	konstantinos	konstantinos	PROPN
dpc-5316	3	25	theodoropoulos1	theodoropoulos1	PROPN
dpc-5316	3	26	,	,	PUNCT
dpc-5316	3	27	anna	anna	PROPN
dpc-5316	3	28	syrmali1	syrmali1	PROPN
dpc-5316	3	29	,	,	PUNCT
dpc-5316	3	30	georgia	georgia	PROPN
dpc-5316	3	31	pappa1	pappa1	PROPN
dpc-5316	3	32	,	,	PUNCT
dpc-5316	3	33	alexandros	alexandros	PROPN
dpc-5316	3	34	katoulis1	katoulis1	VERB
dpc-5316	3	35	1	1	NUM
dpc-5316	3	36	2nd	2nd	ADJ
dpc-5316	3	37	department	department	NOUN
dpc-5316	3	38	of	of	ADP
dpc-5316	3	39	dermatology	dermatology	NOUN
dpc-5316	3	40	and	and	CCONJ
dpc-5316	3	41	venereology	venereology	NOUN
dpc-5316	3	42	,	,	PUNCT
dpc-5316	3	43	national	national	ADJ
dpc-5316	3	44	and	and	CCONJ
dpc-5316	3	45	kapodistrian	kapodistrian	ADJ
dpc-5316	3	46	university	university	PROPN
dpc-5316	3	47	of	of	ADP
dpc-5316	3	48	athens	athens	PROPN
dpc-5316	3	49	,	,	PUNCT
dpc-5316	3	50	medical	medical	ADJ
dpc-5316	3	51	school	school	NOUN
dpc-5316	3	52	,	,	PUNCT
dpc-5316	3	53	“	"	PUNCT
dpc-5316	3	54	attikon	attikon	ADJ
dpc-5316	3	55	”	"	PUNCT
dpc-5316	3	56	general	general	ADJ
dpc-5316	3	57	university	university	NOUN
dpc-5316	3	58	hospital	hospital	NOUN
dpc-5316	3	59	,	,	PUNCT
dpc-5316	3	60	athens	athens	PROPN
dpc-5316	3	61	,	,	PUNCT
dpc-5316	3	62	greece	greece	PROPN
dpc-5316	3	63	key	key	ADJ
dpc-5316	3	64	words	word	NOUN
dpc-5316	3	65	:	:	PUNCT
dpc-5316	3	66	erythroderma	erythroderma	NOUN
dpc-5316	3	67	,	,	PUNCT
dpc-5316	3	68	bimekizumab	bimekizumab	ADV
dpc-5316	3	69	,	,	PUNCT
dpc-5316	3	70	pityriasis	pityriasis	NOUN
dpc-5316	3	71	rubra	rubra	NOUN
dpc-5316	3	72	pilaris	pilaris	NOUN
dpc-5316	3	73	,	,	PUNCT
dpc-5316	3	74	refractory	refractory	NOUN
dpc-5316	3	75	erythroderma	erythroderma	NOUN
dpc-5316	3	76	treatment	treatment	NOUN
dpc-5316	3	77	,	,	PUNCT
dpc-5316	3	78	bimekizumab	bimekizumab	NOUN
dpc-5316	3	79	efficacy	efficacy	PROPN
dpc-5316	3	80	citation	citation	NOUN
dpc-5316	3	81	:	:	PUNCT
dpc-5316	3	82	theotokoglou	theotokoglou	PROPN
dpc-5316	3	83	s	s	PROPN
dpc-5316	3	84	,	,	PUNCT
dpc-5316	3	85	sgouros	sgouro	NOUN
dpc-5316	3	86	d	d	NOUN
dpc-5316	3	87	,	,	PUNCT
dpc-5316	3	88	theodoropoulos	theodoropoulos	PROPN
dpc-5316	3	89	k	k	PROPN
dpc-5316	3	90	,	,	PUNCT
dpc-5316	3	91	et	et	PROPN
dpc-5316	3	92	al	al	PROPN
dpc-5316	3	93	.	.	PROPN
dpc-5316	3	94	efficacy	efficacy	PROPN
dpc-5316	3	95	of	of	ADP
dpc-5316	3	96	bimekizumab	bimekizumab	NOUN
dpc-5316	3	97	in	in	ADP
dpc-5316	3	98	the	the	DET
dpc-5316	3	99	management	management	NOUN
dpc-5316	3	100	of	of	ADP
dpc-5316	3	101	refractory	refractory	NOUN
dpc-5316	3	102	erythrodermic	erythrodermic	ADJ
dpc-5316	3	103	pityriasis	pityriasis	NOUN
dpc-5316	3	104	rubra	rubra	NOUN
dpc-5316	3	105	pilaris	pilaris	NOUN
dpc-5316	3	106	:	:	PUNCT
dpc-5316	3	107	clinical	clinical	ADJ
dpc-5316	3	108	insights	insight	NOUN
dpc-5316	3	109	.	.	PUNCT
dpc-5316	4	1	dermatol	dermatol	NOUN
dpc-5316	4	2	pract	pract	PROPN
dpc-5316	4	3	concept	concept	NOUN
dpc-5316	4	4	.	.	PUNCT
dpc-5316	5	1	2025;15(3):5316	2025;15(3):5316	NUM
dpc-5316	5	2	.	.	PUNCT
dpc-5316	5	3	doi	doi	NOUN
dpc-5316	5	4	:	:	PUNCT
dpc-5316	5	5	https://doi.org/10.5826/dpc.1503a5316	https://doi.org/10.5826/dpc.1503a5316	PROPN
dpc-5316	5	6	accepted	accept	VERB
dpc-5316	5	7	:	:	PUNCT
dpc-5316	5	8	january	january	PROPN
dpc-5316	5	9	21	21	NUM
dpc-5316	5	10	,	,	PUNCT
dpc-5316	5	11	2025	2025	NUM
dpc-5316	5	12	;	;	PUNCT
dpc-5316	5	13	published	publish	VERB
dpc-5316	5	14	:	:	PUNCT
dpc-5316	5	15	july	july	PROPN
dpc-5316	5	16	2025	2025	NUM
dpc-5316	5	17	copyright	copyright	NOUN
dpc-5316	5	18	:	:	PUNCT
dpc-5316	6	1	©	©	PROPN
dpc-5316	6	2	2025	2025	NUM
dpc-5316	6	3	theotokoglou	theotokoglou	NOUN
dpc-5316	6	4	et	et	PROPN
dpc-5316	6	5	al	al	PROPN
dpc-5316	6	6	.	.	PUNCT
dpc-5316	7	1	this	this	PRON
dpc-5316	7	2	is	be	AUX
dpc-5316	7	3	an	an	DET
dpc-5316	7	4	open	open	ADJ
dpc-5316	7	5	-	-	PUNCT
dpc-5316	7	6	access	access	NOUN
dpc-5316	7	7	article	article	NOUN
dpc-5316	7	8	distributed	distribute	VERB
dpc-5316	7	9	under	under	ADP
dpc-5316	7	10	the	the	DET
dpc-5316	7	11	terms	term	NOUN
dpc-5316	7	12	of	of	ADP
dpc-5316	7	13	the	the	DET
dpc-5316	7	14	creative	creative	ADJ
dpc-5316	7	15	commons	common	NOUN
dpc-5316	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5316	7	17	license	license	NOUN
dpc-5316	7	18	(	(	PUNCT
dpc-5316	7	19	by	by	ADP
dpc-5316	7	20	-	-	PUNCT
dpc-5316	7	21	nc-4.0	nc-4.0	NOUN
dpc-5316	7	22	)	)	PUNCT
dpc-5316	7	23	,	,	PUNCT
dpc-5316	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5316	7	25	,	,	PUNCT
dpc-5316	7	26	which	which	PRON
dpc-5316	7	27	permits	permit	VERB
dpc-5316	7	28	unrestricted	unrestricted	ADJ
dpc-5316	7	29	noncommercial	noncommercial	ADJ
dpc-5316	7	30	use	use	NOUN
dpc-5316	7	31	,	,	PUNCT
dpc-5316	7	32	distribution	distribution	NOUN
dpc-5316	7	33	,	,	PUNCT
dpc-5316	7	34	and	and	CCONJ
dpc-5316	7	35	reproduction	reproduction	NOUN
dpc-5316	7	36	in	in	ADP
dpc-5316	7	37	any	any	DET
dpc-5316	7	38	medium	medium	NOUN
dpc-5316	7	39	,	,	PUNCT
dpc-5316	7	40	provided	provide	VERB
dpc-5316	7	41	the	the	DET
dpc-5316	7	42	original	original	ADJ
dpc-5316	7	43	authors	author	NOUN
dpc-5316	7	44	and	and	CCONJ
dpc-5316	7	45	source	source	NOUN
dpc-5316	7	46	are	be	AUX
dpc-5316	7	47	credited	credit	VERB
dpc-5316	7	48	.	.	PUNCT
dpc-5316	8	1	funding	funding	NOUN
dpc-5316	8	2	:	:	PUNCT
dpc-5316	8	3	none	none	NOUN
dpc-5316	8	4	.	.	PUNCT
dpc-5316	9	1	competing	compete	VERB
dpc-5316	9	2	interests	interest	NOUN
dpc-5316	9	3	:	:	PUNCT
dpc-5316	9	4	none	none	NOUN
dpc-5316	9	5	.	.	PUNCT
dpc-5316	10	1	authorship	authorship	NOUN
dpc-5316	10	2	:	:	PUNCT
dpc-5316	10	3	all	all	DET
dpc-5316	10	4	authors	author	NOUN
dpc-5316	10	5	have	have	AUX
dpc-5316	10	6	contributed	contribute	VERB
dpc-5316	10	7	significantly	significantly	ADV
dpc-5316	10	8	to	to	ADP
dpc-5316	10	9	this	this	DET
dpc-5316	10	10	publication	publication	NOUN
dpc-5316	10	11	.	.	PUNCT
dpc-5316	11	1	corresponding	correspond	VERB
dpc-5316	11	2	author	author	NOUN
dpc-5316	11	3	:	:	PUNCT
dpc-5316	11	4	georgia	georgia	PROPN
dpc-5316	11	5	pappa	pappa	PROPN
dpc-5316	11	6	,	,	PUNCT
dpc-5316	11	7	“	"	PUNCT
dpc-5316	11	8	attikon	attikon	ADJ
dpc-5316	11	9	”	"	PUNCT
dpc-5316	11	10	general	general	ADJ
dpc-5316	11	11	university	university	NOUN
dpc-5316	11	12	hospital	hospital	NOUN
dpc-5316	11	13	,	,	PUNCT
dpc-5316	11	14	2nd	2nd	ADJ
dpc-5316	11	15	dept	dept	NOUN
dpc-5316	11	16	.	.	PROPN
dpc-5316	11	17	of	of	ADP
dpc-5316	11	18	dermatology	dermatology	NOUN
dpc-5316	11	19	-	-	PUNCT
dpc-5316	11	20	venereology	venereology	NOUN
dpc-5316	11	21	,	,	PUNCT
dpc-5316	11	22	athens	athens	PROPN
dpc-5316	11	23	,	,	PUNCT
dpc-5316	11	24	greece	greece	PROPN
dpc-5316	11	25	.	.	PUNCT
dpc-5316	12	1	e	e	X
dpc-5316	12	2	-	-	NOUN
dpc-5316	12	3	mail	mail	NOUN
dpc-5316	12	4	:	:	PUNCT
dpc-5316	12	5	gpappa100@gmail.com	gpappa100@gmail.com	X
dpc-5316	12	6	introduction	introduction	NOUN
dpc-5316	12	7	erythroderma	erythroderma	NOUN
dpc-5316	12	8	refers	refer	VERB
dpc-5316	12	9	to	to	ADP
dpc-5316	12	10	widespread	widespread	ADJ
dpc-5316	12	11	skin	skin	NOUN
dpc-5316	12	12	reddening	redden	VERB
dpc-5316	12	13	caused	cause	VERB
dpc-5316	12	14	by	by	ADP
dpc-5316	12	15	inflammatory	inflammatory	ADJ
dpc-5316	12	16	dermatoses	dermatosis	NOUN
dpc-5316	12	17	,	,	PUNCT
dpc-5316	12	18	with	with	ADP
dpc-5316	12	19	pityriasis	pityriasis	NOUN
dpc-5316	12	20	rubra	rubra	NOUN
dpc-5316	12	21	pilaris	pilaris	NOUN
dpc-5316	12	22	(	(	PUNCT
dpc-5316	12	23	prp	prp	PROPN
dpc-5316	12	24	)	)	PUNCT
dpc-5316	12	25	being	be	AUX
dpc-5316	12	26	a	a	DET
dpc-5316	12	27	notable	notable	ADJ
dpc-5316	12	28	cause	cause	NOUN
dpc-5316	12	29	.	.	PUNCT
dpc-5316	13	1	while	while	SCONJ
dpc-5316	13	2	prp	prp	PROPN
dpc-5316	13	3	can	can	AUX
dpc-5316	13	4	sometimes	sometimes	ADV
dpc-5316	13	5	resolve	resolve	VERB
dpc-5316	13	6	spontaneously	spontaneously	ADV
dpc-5316	13	7	,	,	PUNCT
dpc-5316	13	8	erythroderma	erythroderma	NOUN
dpc-5316	13	9	requires	require	VERB
dpc-5316	13	10	prompt	prompt	ADJ
dpc-5316	13	11	treatment	treatment	NOUN
dpc-5316	13	12	,	,	PUNCT
dpc-5316	13	13	often	often	ADV
dpc-5316	13	14	posing	pose	VERB
dpc-5316	13	15	a	a	DET
dpc-5316	13	16	challenge	challenge	NOUN
dpc-5316	13	17	.	.	PUNCT
dpc-5316	14	1	traditional	traditional	ADJ
dpc-5316	14	2	therapies	therapy	NOUN
dpc-5316	14	3	like	like	ADP
dpc-5316	14	4	corticosteroids	corticosteroid	NOUN
dpc-5316	14	5	,	,	PUNCT
dpc-5316	14	6	retinoids	retinoid	NOUN
dpc-5316	14	7	,	,	PUNCT
dpc-5316	14	8	immunosuppressants	immunosuppressant	NOUN
dpc-5316	14	9	,	,	PUNCT
dpc-5316	14	10	and	and	CCONJ
dpc-5316	14	11	phototherapy	phototherapy	NOUN
dpc-5316	14	12	have	have	AUX
dpc-5316	14	13	shown	show	VERB
dpc-5316	14	14	limited	limited	ADJ
dpc-5316	14	15	efficacy	efficacy	NOUN
dpc-5316	14	16	[	[	X
dpc-5316	14	17	1	1	NUM
dpc-5316	14	18	]	]	PUNCT
dpc-5316	14	19	.	.	PUNCT
dpc-5316	15	1	though	though	SCONJ
dpc-5316	15	2	no	no	DET
dpc-5316	15	3	biologics	biologic	NOUN
dpc-5316	15	4	are	be	AUX
dpc-5316	15	5	officially	officially	ADV
dpc-5316	15	6	approved	approve	VERB
dpc-5316	15	7	for	for	ADP
dpc-5316	15	8	prp	prp	NOUN
dpc-5316	15	9	,	,	PUNCT
dpc-5316	15	10	il-17	il-17	NUM
dpc-5316	15	11	,	,	PUNCT
dpc-5316	15	12	il-12/23	il-12/23	PROPN
dpc-5316	15	13	,	,	PUNCT
dpc-5316	15	14	and	and	CCONJ
dpc-5316	15	15	il-23	il-23	NOUN
dpc-5316	15	16	inhibitors	inhibitor	NOUN
dpc-5316	15	17	are	be	AUX
dpc-5316	15	18	increasingly	increasingly	ADV
dpc-5316	15	19	used	use	VERB
dpc-5316	15	20	[	[	PUNCT
dpc-5316	15	21	1	1	NUM
dpc-5316	15	22	-	-	SYM
dpc-5316	15	23	3	3	NUM
dpc-5316	15	24	]	]	PUNCT
dpc-5316	15	25	.	.	PUNCT
dpc-5316	16	1	elevated	elevated	PROPN
dpc-5316	16	2	il-17a	il-17a	PROPN
dpc-5316	16	3	and	and	CCONJ
dpc-5316	16	4	il-17f	il-17f	ADJ
dpc-5316	16	5	levels	level	NOUN
dpc-5316	16	6	in	in	ADP
dpc-5316	16	7	prp	prp	PROPN
dpc-5316	16	8	suggest	suggest	VERB
dpc-5316	16	9	bimekizumab	bimekizumab	PROPN
dpc-5316	16	10	,	,	PUNCT
dpc-5316	16	11	a	a	DET
dpc-5316	16	12	biologic	biologic	NOUN
dpc-5316	16	13	targeting	target	VERB
dpc-5316	16	14	both	both	PRON
dpc-5316	16	15	,	,	PUNCT
dpc-5316	16	16	as	as	ADP
dpc-5316	16	17	a	a	DET
dpc-5316	16	18	promising	promising	ADJ
dpc-5316	16	19	option	option	NOUN
dpc-5316	16	20	[	[	X
dpc-5316	16	21	4	4	NUM
dpc-5316	16	22	]	]	PUNCT
dpc-5316	16	23	.	.	PUNCT
dpc-5316	17	1	we	we	PRON
dpc-5316	17	2	herein	herein	VERB
dpc-5316	17	3	present	present	VERB
dpc-5316	17	4	a	a	DET
dpc-5316	17	5	case	case	NOUN
dpc-5316	17	6	demonstrating	demonstrate	VERB
dpc-5316	17	7	its	its	PRON
dpc-5316	17	8	potential	potential	ADJ
dpc-5316	17	9	effectiveness	effectiveness	NOUN
dpc-5316	17	10	in	in	ADP
dpc-5316	17	11	prp	prp	PROPN
dpc-5316	17	12	management	management	NOUN
dpc-5316	17	13	.	.	PUNCT
dpc-5316	18	1	case	case	NOUN
dpc-5316	18	2	presentation	presentation	NOUN
dpc-5316	18	3	a	a	DET
dpc-5316	18	4	42	42	NUM
dpc-5316	18	5	-	-	PUNCT
dpc-5316	18	6	year	year	NOUN
dpc-5316	18	7	-	-	PUNCT
dpc-5316	18	8	old	old	ADJ
dpc-5316	18	9	white	white	ADJ
dpc-5316	18	10	male	male	NOUN
dpc-5316	18	11	presented	present	VERB
dpc-5316	18	12	with	with	ADP
dpc-5316	18	13	widespread	widespread	ADJ
dpc-5316	18	14	erythema	erythema	NOUN
dpc-5316	18	15	that	that	PRON
dpc-5316	18	16	had	have	AUX
dpc-5316	18	17	begun	begin	VERB
dpc-5316	18	18	three	three	NUM
dpc-5316	18	19	months	month	NOUN
dpc-5316	18	20	earlier	early	ADV
dpc-5316	18	21	as	as	ADP
dpc-5316	18	22	fine	fine	ADJ
dpc-5316	18	23	scaling	scaling	NOUN
dpc-5316	18	24	and	and	CCONJ
dpc-5316	18	25	redness	redness	NOUN
dpc-5316	18	26	on	on	ADP
dpc-5316	18	27	the	the	DET
dpc-5316	18	28	scalp	scalp	NOUN
dpc-5316	18	29	.	.	PUNCT
dpc-5316	19	1	he	he	PRON
dpc-5316	19	2	reported	report	VERB
dpc-5316	19	3	mild	mild	ADJ
dpc-5316	19	4	pruritus	pruritus	NOUN
dpc-5316	19	5	,	,	PUNCT
dpc-5316	19	6	without	without	ADP
dpc-5316	19	7	fever	fever	NOUN
dpc-5316	19	8	or	or	CCONJ
dpc-5316	19	9	other	other	ADJ
dpc-5316	19	10	systemic	systemic	ADJ
dpc-5316	19	11	symptoms	symptom	NOUN
dpc-5316	19	12	.	.	PUNCT
dpc-5316	20	1	his	his	PRON
dpc-5316	20	2	medical	medical	ADJ
dpc-5316	20	3	history	history	NOUN
dpc-5316	20	4	was	be	AUX
dpc-5316	20	5	unremarkable	unremarkable	ADJ
dpc-5316	20	6	,	,	PUNCT
dpc-5316	20	7	and	and	CCONJ
dpc-5316	20	8	there	there	PRON
dpc-5316	20	9	was	be	VERB
dpc-5316	20	10	no	no	DET
dpc-5316	20	11	family	family	NOUN
dpc-5316	20	12	history	history	NOUN
dpc-5316	20	13	of	of	ADP
dpc-5316	20	14	skin	skin	NOUN
dpc-5316	20	15	diseases	disease	NOUN
dpc-5316	20	16	.	.	PUNCT
dpc-5316	21	1	physical	physical	ADJ
dpc-5316	21	2	examination	examination	NOUN
dpc-5316	21	3	revealed	reveal	VERB
dpc-5316	21	4	a	a	DET
dpc-5316	21	5	pink	pink	ADV
dpc-5316	21	6	-	-	PUNCT
dpc-5316	21	7	red	red	VERB
dpc-5316	21	8	-	-	PUNCT
dpc-5316	21	9	to	to	ADP
dpc-5316	21	10	-	-	PUNCT
dpc-5316	21	11	salmon	salmon	NOUN
dpc-5316	21	12	colored	color	VERB
dpc-5316	21	13	erythroderma	erythroderma	NOUN
dpc-5316	21	14	with	with	ADP
dpc-5316	21	15	a	a	DET
dpc-5316	21	16	fine	fine	ADJ
dpc-5316	21	17	epidermal	epidermal	ADJ
dpc-5316	21	18	scale	scale	NOUN
dpc-5316	21	19	,	,	PUNCT
dpc-5316	21	20	which	which	PRON
dpc-5316	21	21	was	be	AUX
dpc-5316	21	22	thicker	thick	ADJ
dpc-5316	21	23	and	and	CCONJ
dpc-5316	21	24	more	more	ADJ
dpc-5316	21	25	adherent	adherent	NOUN
dpc-5316	21	26	on	on	ADP
dpc-5316	21	27	the	the	DET
dpc-5316	21	28	face	face	NOUN
dpc-5316	21	29	and	and	CCONJ
dpc-5316	21	30	scalp	scalp	NOUN
dpc-5316	21	31	.	.	PUNCT
dpc-5316	22	1	the	the	DET
dpc-5316	22	2	involved	involved	ADJ
dpc-5316	22	3	skin	skin	NOUN
dpc-5316	22	4	was	be	AUX
dpc-5316	22	5	sharply	sharply	ADV
dpc-5316	22	6	demarcated	demarcate	VERB
dpc-5316	22	7	from	from	ADP
dpc-5316	22	8	the	the	DET
dpc-5316	22	9	adjacent	adjacent	ADJ
dpc-5316	22	10	uninvolved	uninvolved	ADJ
dpc-5316	22	11	skin	skin	NOUN
dpc-5316	22	12	,	,	PUNCT
dpc-5316	22	13	creating	create	VERB
dpc-5316	22	14	“	"	PUNCT
dpc-5316	22	15	islands	island	NOUN
dpc-5316	22	16	of	of	ADP
dpc-5316	22	17	sparing	sparing	NOUN
dpc-5316	22	18	,	,	PUNCT
dpc-5316	22	19	”	"	PUNCT
dpc-5316	22	20	a	a	DET
dpc-5316	22	21	hallmark	hallmark	NOUN
dpc-5316	22	22	of	of	ADP
dpc-5316	22	23	prp	prp	PROPN
dpc-5316	22	24	(	(	PUNCT
dpc-5316	22	25	figure	figure	NOUN
dpc-5316	22	26	1	1	NUM
dpc-5316	22	27	)	)	PUNCT
dpc-5316	22	28	.	.	PUNCT
dpc-5316	23	1	moderate	moderate	ADJ
dpc-5316	23	2	palmoplantar	palmoplantar	PROPN
dpc-5316	23	3	keratoderma	keratoderma	PROPN
dpc-5316	23	4	was	be	AUX
dpc-5316	23	5	noted	note	VERB
dpc-5316	23	6	,	,	PUNCT
dpc-5316	23	7	without	without	ADP
dpc-5316	23	8	onychodystrophy	onychodystrophy	NOUN
dpc-5316	23	9	,	,	PUNCT
dpc-5316	23	10	lymphadenopathy	lymphadenopathy	ADJ
dpc-5316	23	11	,	,	PUNCT
dpc-5316	23	12	or	or	CCONJ
dpc-5316	23	13	organomegaly	organomegaly	NOUN
dpc-5316	23	14	.	.	PUNCT
dpc-5316	24	1	a	a	DET
dpc-5316	24	2	prior	prior	ADJ
dpc-5316	24	3	dermatology	dermatology	NOUN
dpc-5316	24	4	consultation	consultation	NOUN
dpc-5316	24	5	,	,	PUNCT
dpc-5316	24	6	including	include	VERB
dpc-5316	24	7	a	a	DET
dpc-5316	24	8	skin	skin	NOUN
dpc-5316	24	9	biopsy	biopsy	NOUN
dpc-5316	24	10	,	,	PUNCT
dpc-5316	24	11	had	have	AUX
dpc-5316	24	12	led	lead	VERB
dpc-5316	24	13	to	to	ADP
dpc-5316	24	14	treatment	treatment	NOUN
dpc-5316	24	15	with	with	ADP
dpc-5316	24	16	topical	topical	ADJ
dpc-5316	24	17	corticosteroids	corticosteroid	NOUN
dpc-5316	24	18	and	and	CCONJ
dpc-5316	24	19	emollients	emollient	NOUN
dpc-5316	24	20	,	,	PUNCT
dpc-5316	24	21	with	with	ADP
dpc-5316	24	22	no	no	DET
dpc-5316	24	23	improvement	improvement	NOUN
dpc-5316	24	24	.	.	PUNCT
dpc-5316	25	1	laboratory	laboratory	NOUN
dpc-5316	25	2	workup	workup	PROPN
dpc-5316	25	3	,	,	PUNCT
dpc-5316	25	4	including	include	VERB
dpc-5316	25	5	cbc	cbc	PROPN
dpc-5316	25	6	,	,	PUNCT
dpc-5316	25	7	crp	crp	PROPN
dpc-5316	25	8	,	,	PUNCT
dpc-5316	25	9	esr	esr	PROPN
dpc-5316	25	10	,	,	PUNCT
dpc-5316	25	11	and	and	CCONJ
dpc-5316	25	12	tests	test	NOUN
dpc-5316	25	13	for	for	ADP
dpc-5316	25	14	hepatitis	hepatitis	PROPN
dpc-5316	25	15	b	b	PROPN
dpc-5316	25	16	,	,	PUNCT
dpc-5316	25	17	c	c	NOUN
dpc-5316	25	18	,	,	PUNCT
dpc-5316	25	19	and	and	CCONJ
dpc-5316	25	20	hiv	hiv	PROPN
dpc-5316	25	21	,	,	PUNCT
dpc-5316	25	22	was	be	AUX
dpc-5316	25	23	unremarkable	unremarkable	ADJ
dpc-5316	25	24	.	.	PUNCT
dpc-5316	26	1	lupus	lupus	PROPN
dpc-5316	26	2	erythematosus	erythematosus	PROPN
dpc-5316	26	3	was	be	AUX
dpc-5316	26	4	excluded	exclude	VERB
dpc-5316	26	5	by	by	ADP
dpc-5316	26	6	normal	normal	ADJ
dpc-5316	26	7	complement	complement	NOUN
dpc-5316	26	8	levels	level	NOUN
dpc-5316	26	9	and	and	CCONJ
dpc-5316	26	10	negative	negative	ADJ
dpc-5316	26	11	ana	ana	PROPN
dpc-5316	26	12	and	and	CCONJ
dpc-5316	26	13	anti	anti	ADJ
dpc-5316	26	14	-	-	ADJ
dpc-5316	26	15	dsdna	dsdna	ADJ
dpc-5316	26	16	tests	test	NOUN
dpc-5316	26	17	.	.	PUNCT
dpc-5316	27	1	flow	flow	NOUN
dpc-5316	27	2	cytometry	cytometry	NOUN
dpc-5316	27	3	was	be	AUX
dpc-5316	27	4	performed	perform	VERB
dpc-5316	27	5	to	to	PART
dpc-5316	27	6	rule	rule	VERB
dpc-5316	27	7	out	out	ADP
dpc-5316	27	8	cutaneous	cutaneous	ADJ
dpc-5316	27	9	lymphomas	lymphoma	NOUN
dpc-5316	27	10	.	.	PUNCT
dpc-5316	28	1	to	to	PART
dpc-5316	28	2	control	control	VERB
dpc-5316	28	3	the	the	DET
dpc-5316	28	4	erythroderma	erythroderma	NOUN
dpc-5316	28	5	the	the	DET
dpc-5316	28	6	patient	patient	NOUN
dpc-5316	28	7	was	be	AUX
dpc-5316	28	8	initially	initially	ADV
dpc-5316	28	9	administered	administer	VERB
dpc-5316	28	10	methylprednisolone	methylprednisolone	NOUN
dpc-5316	28	11	60	60	NUM
dpc-5316	28	12	mg	mg	NUM
dpc-5316	28	13	2	2	NUM
dpc-5316	28	14	research	research	NOUN
dpc-5316	28	15	letter	letter	NOUN
dpc-5316	29	1	|	|	ADV
dpc-5316	29	2	dermatol	dermatol	ADJ
dpc-5316	29	3	pract	pract	NOUN
dpc-5316	29	4	concept	concept	NOUN
dpc-5316	29	5	.	.	PUNCT
dpc-5316	30	1	2025;15(3):5316	2025;15(3):5316	NUM
dpc-5316	30	2	daily	daily	ADJ
dpc-5316	30	3	(	(	PUNCT
dpc-5316	30	4	0.75	0.75	NUM
dpc-5316	30	5	mg	mg	PROPN
dpc-5316	30	6	/	/	SYM
dpc-5316	30	7	kg	kg	PROPN
dpc-5316	30	8	twice	twice	DET
dpc-5316	30	9	a	a	DET
dpc-5316	30	10	day	day	NOUN
dpc-5316	30	11	)	)	PUNCT
dpc-5316	30	12	.	.	PUNCT
dpc-5316	31	1	skin	skin	NOUN
dpc-5316	31	2	histopathology	histopathology	NOUN
dpc-5316	31	3	revealed	reveal	VERB
dpc-5316	31	4	hyperkeratosis	hyperkeratosis	NOUN
dpc-5316	31	5	,	,	PUNCT
dpc-5316	31	6	parakeratosis	parakeratosis	NOUN
dpc-5316	31	7	,	,	PUNCT
dpc-5316	31	8	mild	mild	ADJ
dpc-5316	31	9	epidermal	epidermal	ADJ
dpc-5316	31	10	hyperplasia	hyperplasia	NOUN
dpc-5316	31	11	,	,	PUNCT
dpc-5316	31	12	spongiosis	spongiosis	NOUN
dpc-5316	31	13	,	,	PUNCT
dpc-5316	31	14	and	and	CCONJ
dpc-5316	31	15	lymphocytic	lymphocytic	ADJ
dpc-5316	31	16	infiltration	infiltration	NOUN
dpc-5316	31	17	in	in	ADP
dpc-5316	31	18	the	the	DET
dpc-5316	31	19	perivascular	perivascular	ADJ
dpc-5316	31	20	and	and	CCONJ
dpc-5316	31	21	upper	upper	ADJ
dpc-5316	31	22	dermis	dermis	NOUN
dpc-5316	31	23	;	;	PUNCT
dpc-5316	31	24	findings	finding	NOUN
dpc-5316	31	25	consistent	consistent	ADJ
dpc-5316	31	26	with	with	ADP
dpc-5316	31	27	prp	prp	NOUN
dpc-5316	31	28	.	.	PUNCT
dpc-5316	32	1	after	after	ADP
dpc-5316	32	2	10	10	NUM
dpc-5316	32	3	days	day	NOUN
dpc-5316	32	4	of	of	ADP
dpc-5316	32	5	corticosteroids	corticosteroid	NOUN
dpc-5316	32	6	with	with	ADP
dpc-5316	32	7	no	no	DET
dpc-5316	32	8	improvement	improvement	NOUN
dpc-5316	32	9	,	,	PUNCT
dpc-5316	32	10	acitretin	acitretin	VERB
dpc-5316	32	11	30	30	NUM
dpc-5316	32	12	mg	mg	NUM
dpc-5316	32	13	/	/	SYM
dpc-5316	32	14	day	day	NOUN
dpc-5316	32	15	was	be	AUX
dpc-5316	32	16	initiated	initiate	VERB
dpc-5316	32	17	but	but	CCONJ
dpc-5316	32	18	proved	prove	VERB
dpc-5316	32	19	ineffective	ineffective	ADJ
dpc-5316	32	20	after	after	ADP
dpc-5316	32	21	one	one	NUM
dpc-5316	32	22	month	month	NOUN
dpc-5316	32	23	.	.	PUNCT
dpc-5316	33	1	it	it	PRON
dpc-5316	33	2	was	be	AUX
dpc-5316	33	3	replaced	replace	VERB
dpc-5316	33	4	with	with	ADP
dpc-5316	33	5	subcutaneous	subcutaneous	ADJ
dpc-5316	33	6	methotrexate	methotrexate	NOUN
dpc-5316	33	7	15	15	NUM
dpc-5316	33	8	mg	mg	NUM
dpc-5316	33	9	/	/	SYM
dpc-5316	33	10	week	week	NOUN
dpc-5316	33	11	and	and	CCONJ
dpc-5316	33	12	folic	folic	ADJ
dpc-5316	33	13	acid	acid	NOUN
dpc-5316	33	14	5	5	NUM
dpc-5316	33	15	mg	mg	NUM
dpc-5316	33	16	/	/	SYM
dpc-5316	33	17	week	week	NOUN
dpc-5316	33	18	.	.	PUNCT
dpc-5316	34	1	despite	despite	SCONJ
dpc-5316	34	2	two	two	NUM
dpc-5316	34	3	months	month	NOUN
dpc-5316	34	4	of	of	ADP
dpc-5316	34	5	methotrexate	methotrexate	NOUN
dpc-5316	34	6	therapy	therapy	NOUN
dpc-5316	34	7	,	,	PUNCT
dpc-5316	34	8	the	the	DET
dpc-5316	34	9	patient	patient	NOUN
dpc-5316	34	10	showed	show	VERB
dpc-5316	34	11	no	no	DET
dpc-5316	34	12	significant	significant	ADJ
dpc-5316	34	13	skin	skin	NOUN
dpc-5316	34	14	improvement	improvement	NOUN
dpc-5316	34	15	.	.	PUNCT
dpc-5316	35	1	at	at	ADP
dpc-5316	35	2	this	this	DET
dpc-5316	35	3	stage	stage	NOUN
dpc-5316	35	4	,	,	PUNCT
dpc-5316	35	5	it	it	PRON
dpc-5316	35	6	was	be	AUX
dpc-5316	35	7	decided	decide	VERB
dpc-5316	35	8	to	to	PART
dpc-5316	35	9	switch	switch	VERB
dpc-5316	35	10	from	from	ADP
dpc-5316	35	11	conventional	conventional	ADJ
dpc-5316	35	12	treatments	treatment	NOUN
dpc-5316	35	13	to	to	ADP
dpc-5316	35	14	biologic	biologic	NOUN
dpc-5316	35	15	therapy	therapy	NOUN
dpc-5316	35	16	.	.	PUNCT
dpc-5316	36	1	with	with	ADP
dpc-5316	36	2	informed	informed	ADJ
dpc-5316	36	3	consent	consent	NOUN
dpc-5316	36	4	,	,	PUNCT
dpc-5316	36	5	bimekizumab	bimekizumab	CCONJ
dpc-5316	36	6	was	be	AUX
dpc-5316	36	7	administered	administer	VERB
dpc-5316	36	8	at	at	ADP
dpc-5316	36	9	the	the	DET
dpc-5316	36	10	psoriasis	psoriasis	NOUN
dpc-5316	36	11	-	-	PUNCT
dpc-5316	36	12	approved	approve	VERB
dpc-5316	36	13	dose	dose	NOUN
dpc-5316	36	14	(	(	PUNCT
dpc-5316	36	15	320	320	NUM
dpc-5316	36	16	mg	mg	NOUN
dpc-5316	36	17	subcutaneously	subcutaneously	ADV
dpc-5316	36	18	at	at	ADP
dpc-5316	36	19	weeks	week	NOUN
dpc-5316	36	20	0	0	NUM
dpc-5316	36	21	,	,	PUNCT
dpc-5316	36	22	4	4	NUM
dpc-5316	36	23	,	,	PUNCT
dpc-5316	36	24	8	8	NUM
dpc-5316	36	25	,	,	PUNCT
dpc-5316	36	26	12	12	NUM
dpc-5316	36	27	,	,	PUNCT
dpc-5316	36	28	and	and	CCONJ
dpc-5316	36	29	16	16	NUM
dpc-5316	36	30	,	,	PUNCT
dpc-5316	36	31	then	then	ADV
dpc-5316	36	32	every	every	DET
dpc-5316	36	33	eight	eight	NUM
dpc-5316	36	34	weeks	week	NOUN
dpc-5316	36	35	)	)	PUNCT
dpc-5316	36	36	.	.	PUNCT
dpc-5316	37	1	remarkably	remarkably	ADV
dpc-5316	37	2	,	,	PUNCT
dpc-5316	37	3	near	near	ADV
dpc-5316	37	4	-	-	PUNCT
dpc-5316	37	5	complete	complete	ADJ
dpc-5316	37	6	remission	remission	NOUN
dpc-5316	37	7	of	of	ADP
dpc-5316	37	8	the	the	DET
dpc-5316	37	9	skin	skin	NOUN
dpc-5316	37	10	rash	rash	NOUN
dpc-5316	37	11	was	be	AUX
dpc-5316	37	12	observed	observe	VERB
dpc-5316	37	13	after	after	ADP
dpc-5316	37	14	just	just	ADV
dpc-5316	37	15	two	two	NUM
dpc-5316	37	16	doses	dose	NOUN
dpc-5316	37	17	at	at	ADP
dpc-5316	37	18	weeks	week	NOUN
dpc-5316	37	19	0	0	NUM
dpc-5316	37	20	and	and	CCONJ
dpc-5316	37	21	4	4	NUM
dpc-5316	37	22	(	(	PUNCT
dpc-5316	37	23	figure	figure	NOUN
dpc-5316	37	24	2	2	NUM
dpc-5316	37	25	)	)	PUNCT
dpc-5316	37	26	,	,	PUNCT
dpc-5316	37	27	while	while	SCONJ
dpc-5316	37	28	complete	complete	ADJ
dpc-5316	37	29	remission	remission	NOUN
dpc-5316	37	30	was	be	AUX
dpc-5316	37	31	achieved	achieve	VERB
dpc-5316	37	32	by	by	ADP
dpc-5316	37	33	the	the	DET
dpc-5316	37	34	4th	4th	ADJ
dpc-5316	37	35	dose	dose	NOUN
dpc-5316	37	36	.	.	PUNCT
dpc-5316	38	1	the	the	DET
dpc-5316	38	2	patient	patient	NOUN
dpc-5316	38	3	has	have	AUX
dpc-5316	38	4	been	be	AUX
dpc-5316	38	5	on	on	ADP
dpc-5316	38	6	treatment	treatment	NOUN
dpc-5316	38	7	for	for	ADP
dpc-5316	38	8	11	11	NUM
dpc-5316	38	9	months	month	NOUN
dpc-5316	38	10	,	,	PUNCT
dpc-5316	38	11	with	with	ADP
dpc-5316	38	12	no	no	DET
dpc-5316	38	13	signs	sign	NOUN
dpc-5316	38	14	of	of	ADP
dpc-5316	38	15	recurrence	recurrence	NOUN
dpc-5316	38	16	to	to	ADP
dpc-5316	38	17	date	date	NOUN
dpc-5316	38	18	.	.	PUNCT
dpc-5316	39	1	conclusion	conclusion	NOUN
dpc-5316	39	2	although	although	SCONJ
dpc-5316	39	3	biologic	biologic	NOUN
dpc-5316	39	4	agents	agent	NOUN
dpc-5316	39	5	are	be	AUX
dpc-5316	39	6	not	not	PART
dpc-5316	39	7	officially	officially	ADV
dpc-5316	39	8	indicated	indicate	VERB
dpc-5316	39	9	for	for	ADP
dpc-5316	39	10	prp	prp	NOUN
dpc-5316	39	11	,	,	PUNCT
dpc-5316	39	12	they	they	PRON
dpc-5316	39	13	are	be	AUX
dpc-5316	39	14	increasingly	increasingly	ADV
dpc-5316	39	15	used	use	VERB
dpc-5316	39	16	in	in	ADP
dpc-5316	39	17	severe	severe	ADJ
dpc-5316	39	18	,	,	PUNCT
dpc-5316	39	19	refractory	refractory	NOUN
dpc-5316	39	20	cases	case	NOUN
dpc-5316	39	21	,	,	PUNCT
dpc-5316	39	22	with	with	ADP
dpc-5316	39	23	evidence	evidence	NOUN
dpc-5316	39	24	supporting	support	VERB
dpc-5316	39	25	the	the	DET
dpc-5316	39	26	efficacy	efficacy	NOUN
dpc-5316	39	27	of	of	ADP
dpc-5316	39	28	il-17a	il-17a	PROPN
dpc-5316	39	29	antagonists	antagonist	NOUN
dpc-5316	39	30	[	[	X
dpc-5316	39	31	3	3	NUM
dpc-5316	39	32	]	]	PUNCT
dpc-5316	39	33	.	.	PUNCT
dpc-5316	40	1	bimekizumab	bimekizumab	PROPN
dpc-5316	40	2	,	,	PUNCT
dpc-5316	40	3	a	a	DET
dpc-5316	40	4	newly	newly	ADV
dpc-5316	40	5	approved	approve	VERB
dpc-5316	40	6	biologic	biologic	NOUN
dpc-5316	40	7	targeting	target	VERB
dpc-5316	40	8	il-17a	il-17a	PROPN
dpc-5316	40	9	and	and	CCONJ
dpc-5316	40	10	il-17f	il-17f	NOUN
dpc-5316	40	11	,	,	PUNCT
dpc-5316	40	12	is	be	AUX
dpc-5316	40	13	highly	highly	ADV
dpc-5316	40	14	effective	effective	ADJ
dpc-5316	40	15	in	in	ADP
dpc-5316	40	16	psoriasis	psoriasis	NOUN
dpc-5316	40	17	.	.	PUNCT
dpc-5316	41	1	to	to	ADP
dpc-5316	41	2	date	date	NOUN
dpc-5316	41	3	,	,	PUNCT
dpc-5316	41	4	two	two	NUM
dpc-5316	41	5	published	publish	VERB
dpc-5316	41	6	cases	case	NOUN
dpc-5316	41	7	have	have	AUX
dpc-5316	41	8	reported	report	VERB
dpc-5316	41	9	successful	successful	ADJ
dpc-5316	41	10	prp	prp	NOUN
dpc-5316	41	11	treatment	treatment	NOUN
dpc-5316	41	12	with	with	ADP
dpc-5316	41	13	bimekizumab	bimekizumab	NOUN
dpc-5316	41	14	[	[	X
dpc-5316	41	15	5,6	5,6	NUM
dpc-5316	41	16	]	]	PUNCT
dpc-5316	41	17	.	.	PUNCT
dpc-5316	42	1	unlike	unlike	ADP
dpc-5316	42	2	these	these	DET
dpc-5316	42	3	cases	case	NOUN
dpc-5316	42	4	,	,	PUNCT
dpc-5316	42	5	where	where	SCONJ
dpc-5316	42	6	longer	long	ADJ
dpc-5316	42	7	disease	disease	NOUN
dpc-5316	42	8	duration	duration	NOUN
dpc-5316	42	9	may	may	AUX
dpc-5316	42	10	have	have	AUX
dpc-5316	42	11	influenced	influence	VERB
dpc-5316	42	12	outcomes	outcome	NOUN
dpc-5316	42	13	,	,	PUNCT
dpc-5316	42	14	our	our	PRON
dpc-5316	42	15	patient	patient	NOUN
dpc-5316	42	16	had	have	VERB
dpc-5316	42	17	a	a	DET
dpc-5316	42	18	shorter	short	ADJ
dpc-5316	42	19	disease	disease	NOUN
dpc-5316	42	20	course	course	NOUN
dpc-5316	42	21	and	and	CCONJ
dpc-5316	42	22	achieved	achieve	VERB
dpc-5316	42	23	near	near	ADV
dpc-5316	42	24	-	-	PUNCT
dpc-5316	42	25	complete	complete	ADJ
dpc-5316	42	26	remission	remission	NOUN
dpc-5316	42	27	after	after	ADP
dpc-5316	42	28	just	just	ADV
dpc-5316	42	29	two	two	NUM
dpc-5316	42	30	doses	dose	NOUN
dpc-5316	42	31	.	.	PUNCT
dpc-5316	43	1	while	while	SCONJ
dpc-5316	43	2	evidence	evidence	NOUN
dpc-5316	43	3	suggests	suggest	VERB
dpc-5316	43	4	prp	prp	PROPN
dpc-5316	43	5	responds	respond	VERB
dpc-5316	43	6	variably	variably	ADV
dpc-5316	43	7	to	to	ADP
dpc-5316	43	8	biologics	biologic	NOUN
dpc-5316	43	9	,	,	PUNCT
dpc-5316	43	10	further	further	ADJ
dpc-5316	43	11	studies	study	NOUN
dpc-5316	43	12	are	be	AUX
dpc-5316	43	13	needed	need	VERB
dpc-5316	43	14	to	to	PART
dpc-5316	43	15	assess	assess	VERB
dpc-5316	43	16	bimekizumab	bimekizumab	NOUN
dpc-5316	43	17	efficacy	efficacy	NOUN
dpc-5316	43	18	and	and	CCONJ
dpc-5316	43	19	identify	identify	VERB
dpc-5316	43	20	the	the	DET
dpc-5316	43	21	optimal	optimal	ADJ
dpc-5316	43	22	biologic	biologic	NOUN
dpc-5316	43	23	treatment	treatment	NOUN
dpc-5316	43	24	for	for	ADP
dpc-5316	43	25	prp	prp	NOUN
dpc-5316	43	26	[	[	X
dpc-5316	43	27	1	1	NUM
dpc-5316	43	28	-	-	SYM
dpc-5316	43	29	6	6	NUM
dpc-5316	43	30	]	]	PUNCT
dpc-5316	43	31	.	.	PUNCT
dpc-5316	44	1	figure	figure	NOUN
dpc-5316	44	2	1	1	NUM
dpc-5316	44	3	.	.	PUNCT
dpc-5316	45	1	a	a	DET
dpc-5316	45	2	42	42	NUM
dpc-5316	45	3	-	-	PUNCT
dpc-5316	45	4	year	year	NOUN
dpc-5316	45	5	-	-	PUNCT
dpc-5316	45	6	old	old	ADJ
dpc-5316	45	7	male	male	NOUN
dpc-5316	45	8	with	with	ADP
dpc-5316	45	9	(	(	PUNCT
dpc-5316	45	10	a	a	DET
dpc-5316	45	11	-	-	PUNCT
dpc-5316	45	12	c	c	NOUN
dpc-5316	45	13	)	)	PUNCT
dpc-5316	45	14	pink	pink	ADJ
dpc-5316	45	15	-	-	PUNCT
dpc-5316	45	16	to	to	ADP
dpc-5316	45	17	-	-	PUNCT
dpc-5316	45	18	salmon	salmon	NOUN
dpc-5316	45	19	-	-	PUNCT
dpc-5316	45	20	colored	color	VERB
dpc-5316	45	21	erythroderma	erythroderma	NOUN
dpc-5316	45	22	with	with	ADP
dpc-5316	45	23	distinct	distinct	ADJ
dpc-5316	45	24	“	"	PUNCT
dpc-5316	45	25	islands	island	NOUN
dpc-5316	45	26	of	of	ADP
dpc-5316	45	27	sparing	sparing	NOUN
dpc-5316	45	28	”	"	PUNCT
dpc-5316	45	29	and	and	CCONJ
dpc-5316	45	30	(	(	PUNCT
dpc-5316	45	31	b	b	NOUN
dpc-5316	45	32	)	)	PUNCT
dpc-5316	45	33	moderate	moderate	ADJ
dpc-5316	45	34	orange	orange	ADJ
dpc-5316	45	35	-	-	PUNCT
dpc-5316	45	36	waxy	waxy	NOUN
dpc-5316	45	37	palmoplantar	palmoplantar	NOUN
dpc-5316	45	38	keratoderma	keratoderma	PROPN
dpc-5316	45	39	.	.	PUNCT
dpc-5316	46	1	figure	figure	NOUN
dpc-5316	46	2	2	2	NUM
dpc-5316	46	3	.	.	PUNCT
dpc-5316	47	1	the	the	DET
dpc-5316	47	2	same	same	ADJ
dpc-5316	47	3	patient	patient	NOUN
dpc-5316	47	4	five	five	NUM
dpc-5316	47	5	weeks	week	NOUN
dpc-5316	47	6	after	after	ADP
dpc-5316	47	7	starting	start	VERB
dpc-5316	47	8	bimekizumab	bimekizumab	ADV
dpc-5316	47	9	.	.	PUNCT
dpc-5316	48	1	(	(	PUNCT
dpc-5316	48	2	a	a	X
dpc-5316	48	3	-	-	PUNCT
dpc-5316	48	4	c	c	NOUN
dpc-5316	48	5	)	)	PUNCT
dpc-5316	48	6	near	near	ADV
dpc-5316	48	7	-	-	PUNCT
dpc-5316	48	8	complete	complete	ADJ
dpc-5316	48	9	remission	remission	NOUN
dpc-5316	48	10	of	of	ADP
dpc-5316	48	11	the	the	DET
dpc-5316	48	12	skin	skin	NOUN
dpc-5316	48	13	rash	rash	NOUN
dpc-5316	48	14	is	be	AUX
dpc-5316	48	15	evident	evident	ADJ
dpc-5316	48	16	.	.	PUNCT
dpc-5316	49	1	research	research	NOUN
dpc-5316	49	2	letter	letter	NOUN
dpc-5316	49	3	|	|	ADV
dpc-5316	49	4	dermatol	dermatol	ADJ
dpc-5316	49	5	pract	pract	NOUN
dpc-5316	49	6	concept	concept	NOUN
dpc-5316	49	7	.	.	PUNCT
dpc-5316	50	1	2025;15(3):5316	2025;15(3):5316	NUM
dpc-5316	50	2	3	3	NUM
dpc-5316	50	3	references	reference	NOUN
dpc-5316	50	4	1	1	NUM
dpc-5316	50	5	.	.	PUNCT
dpc-5316	51	1	kromer	kromer	PROPN
dpc-5316	51	2	c	c	PROPN
dpc-5316	51	3	,	,	PUNCT
dpc-5316	51	4	sabat	sabat	PROPN
dpc-5316	51	5	r	r	NOUN
dpc-5316	51	6	,	,	PUNCT
dpc-5316	51	7	celis	celis	PROPN
dpc-5316	51	8	d	d	PROPN
dpc-5316	51	9	,	,	PUNCT
dpc-5316	51	10	et	et	PROPN
dpc-5316	51	11	al	al	PROPN
dpc-5316	51	12	.	.	PUNCT
dpc-5316	52	1	systemic	systemic	ADJ
dpc-5316	52	2	therapies	therapy	NOUN
dpc-5316	52	3	of	of	ADP
dpc-5316	52	4	pityriasis	pityriasis	NOUN
dpc-5316	52	5	rubra	rubra	NOUN
dpc-5316	52	6	pilaris	pilaris	NOUN
dpc-5316	52	7	:	:	PUNCT
dpc-5316	52	8	a	a	DET
dpc-5316	52	9	systematic	systematic	ADJ
dpc-5316	52	10	review	review	NOUN
dpc-5316	52	11	.	.	PUNCT
dpc-5316	53	1	j	j	PROPN
dpc-5316	53	2	dtsch	dtsch	PROPN
dpc-5316	53	3	dermatol	dermatol	NOUN
dpc-5316	53	4	ges	ge	NOUN
dpc-5316	53	5	.	.	PUNCT
dpc-5316	54	1	2019;17(3):243–259	2019;17(3):243–259	PUNCT
dpc-5316	54	2	.	.	X
dpc-5316	55	1	doi	doi	NOUN
dpc-5316	55	2	:	:	PUNCT
dpc-5316	55	3	10.1111	10.1111	NUM
dpc-5316	55	4	/	/	SYM
dpc-5316	55	5	ddg.13718	ddg.13718	PROPN
dpc-5316	55	6	.	.	PUNCT
dpc-5316	56	1	pmid	pmid	NOUN
dpc-5316	56	2	:	:	PUNCT
dpc-5316	56	3	30520557	30520557	NUM
dpc-5316	56	4	.	.	PUNCT
dpc-5316	57	1	2	2	X
dpc-5316	57	2	.	.	X
dpc-5316	57	3	kromer	kromer	PROPN
dpc-5316	57	4	c	c	PROPN
dpc-5316	57	5	,	,	PUNCT
dpc-5316	57	6	schön	schön	PROPN
dpc-5316	57	7	mp	mp	PROPN
dpc-5316	57	8	,	,	PUNCT
dpc-5316	57	9	mössner	mössner	PROPN
dpc-5316	57	10	r.	r.	PROPN
dpc-5316	57	11	treatment	treatment	NOUN
dpc-5316	57	12	of	of	ADP
dpc-5316	57	13	pityriasis	pityriasis	NOUN
dpc-5316	57	14	rubra	rubra	NOUN
dpc-5316	57	15	pilaris	pilaris	NOUN
dpc-5316	57	16	with	with	ADP
dpc-5316	57	17	risankizumab	risankizumab	NOUN
dpc-5316	57	18	in	in	ADP
dpc-5316	57	19	two	two	NUM
dpc-5316	57	20	cases	case	NOUN
dpc-5316	57	21	.	.	PUNCT
dpc-5316	58	1	j	j	NOUN
dpc-5316	58	2	dtsch	dtsch	PROPN
dpc-5316	58	3	dermatol	dermatol	NOUN
dpc-5316	58	4	ges	ge	NOUN
dpc-5316	58	5	.	.	PROPN
dpc-5316	58	6	2021;19(8):1207–1209	2021;19(8):1207–1209	PROPN
dpc-5316	58	7	.	.	PUNCT
dpc-5316	59	1	doi	doi	NOUN
dpc-5316	59	2	:	:	PUNCT
dpc-5316	59	3	10.1111	10.1111	NUM
dpc-5316	59	4	/	/	SYM
dpc-5316	59	5	ddg.14504	ddg.14504	NUM
dpc-5316	59	6	.	.	PUNCT
dpc-5316	60	1	pmid	pmid	NOUN
dpc-5316	60	2	:	:	PUNCT
dpc-5316	60	3	33973380	33973380	NUM
dpc-5316	60	4	.	.	PUNCT
dpc-5316	61	1	3	3	X
dpc-5316	61	2	.	.	X
dpc-5316	61	3	napolitano	napolitano	PROPN
dpc-5316	61	4	m	m	PROPN
dpc-5316	61	5	,	,	PUNCT
dpc-5316	61	6	abeni	abeni	PROPN
dpc-5316	61	7	d	d	PROPN
dpc-5316	61	8	,	,	PUNCT
dpc-5316	61	9	didona	didona	PROPN
dpc-5316	61	10	b.	b.	PROPN
dpc-5316	61	11	biologics	biologics	PROPN
dpc-5316	61	12	for	for	ADP
dpc-5316	61	13	pityriasis	pityriasis	NOUN
dpc-5316	61	14	rubra	rubra	NOUN
dpc-5316	61	15	pilaris	pilaris	NOUN
dpc-5316	61	16	treatment	treatment	NOUN
dpc-5316	61	17	:	:	PUNCT
dpc-5316	61	18	a	a	DET
dpc-5316	61	19	review	review	NOUN
dpc-5316	61	20	of	of	ADP
dpc-5316	61	21	the	the	DET
dpc-5316	61	22	literature	literature	NOUN
dpc-5316	61	23	.	.	PUNCT
dpc-5316	62	1	j	j	PROPN
dpc-5316	62	2	am	be	AUX
dpc-5316	62	3	acad	acad	ADJ
dpc-5316	62	4	dermatol	dermatol	NOUN
dpc-5316	62	5	.	.	PUNCT
dpc-5316	63	1	2018;79(2):353–359.e11	2018;79(2):353–359.e11	VERB
dpc-5316	63	2	.	.	PUNCT
dpc-5316	64	1	doi	doi	NOUN
dpc-5316	64	2	:	:	PUNCT
dpc-5316	64	3	10.1016	10.1016	NUM
dpc-5316	64	4	/	/	SYM
dpc-5316	64	5	j.jaad.2018.03.036	j.jaad.2018.03.036	PROPN
dpc-5316	64	6	.	.	PUNCT
dpc-5316	65	1	pmid	pmid	NOUN
dpc-5316	65	2	:	:	PUNCT
dpc-5316	65	3	29609014	29609014	NUM
dpc-5316	65	4	.	.	PUNCT
dpc-5316	66	1	4	4	X
dpc-5316	66	2	.	.	X
dpc-5316	66	3	feldmeyer	feldmeyer	PROPN
dpc-5316	66	4	l	l	PROPN
dpc-5316	66	5	,	,	PUNCT
dpc-5316	66	6	mylonas	mylonas	PROPN
dpc-5316	66	7	a	a	PRON
dpc-5316	66	8	,	,	PUNCT
dpc-5316	66	9	demaria	demaria	PROPN
dpc-5316	66	10	o	o	NOUN
dpc-5316	66	11	,	,	PUNCT
dpc-5316	66	12	et	et	PROPN
dpc-5316	66	13	al	al	PROPN
dpc-5316	66	14	.	.	PUNCT
dpc-5316	67	1	interleukin	interleukin	NOUN
dpc-5316	67	2	23	23	NUM
dpc-5316	67	3	-	-	PUNCT
dpc-5316	67	4	helper	helper	NOUN
dpc-5316	67	5	t	t	PROPN
dpc-5316	67	6	cell	cell	NOUN
dpc-5316	67	7	17	17	NUM
dpc-5316	67	8	axis	axis	NOUN
dpc-5316	67	9	as	as	ADP
dpc-5316	67	10	a	a	DET
dpc-5316	67	11	treatment	treatment	NOUN
dpc-5316	67	12	target	target	NOUN
dpc-5316	67	13	for	for	ADP
dpc-5316	67	14	pityriasis	pityriasis	NOUN
dpc-5316	67	15	rubra	rubra	NOUN
dpc-5316	67	16	pilaris	pilaris	NOUN
dpc-5316	67	17	.	.	PUNCT
dpc-5316	68	1	jama	jama	PROPN
dpc-5316	68	2	dermatol	dermatol	NOUN
dpc-5316	68	3	.	.	PUNCT
dpc-5316	69	1	2017;153(4):304–308	2017;153(4):304–308	X
dpc-5316	69	2	.	.	PUNCT
dpc-5316	69	3	doi	doi	NOUN
dpc-5316	69	4	:	:	PUNCT
dpc-5316	69	5	10.1001	10.1001	NUM
dpc-5316	69	6	/	/	SYM
dpc-5316	69	7	jamadermatol.2016.5384	jamadermatol.2016.5384	PROPN
dpc-5316	69	8	.	.	PUNCT
dpc-5316	70	1	pmid	pmid	NOUN
dpc-5316	70	2	:	:	PUNCT
dpc-5316	70	3	28122069	28122069	NUM
dpc-5316	70	4	.	.	PUNCT
dpc-5316	71	1	5	5	NUM
dpc-5316	71	2	.	.	X
dpc-5316	71	3	saad	saad	PROPN
dpc-5316	71	4	m	m	PROPN
dpc-5316	71	5	,	,	PUNCT
dpc-5316	71	6	bose	bose	PROPN
dpc-5316	71	7	r.	r.	PROPN
dpc-5316	71	8	erythrodermic	erythrodermic	PROPN
dpc-5316	71	9	pityriasis	pityriasis	PROPN
dpc-5316	71	10	rubra	rubra	NOUN
dpc-5316	71	11	pilaris	pilaris	NOUN
dpc-5316	71	12	following	follow	VERB
dpc-5316	71	13	sars	sar	NOUN
dpc-5316	71	14	-	-	PUNCT
dpc-5316	71	15	cov-2	cov-2	PART
dpc-5316	71	16	vaccination	vaccination	NOUN
dpc-5316	71	17	treated	treat	VERB
dpc-5316	71	18	with	with	ADP
dpc-5316	71	19	bimekizumab	bimekizumab	NOUN
dpc-5316	71	20	.	.	PUNCT
dpc-5316	72	1	jaad	jaad	NOUN
dpc-5316	72	2	case	case	NOUN
dpc-5316	72	3	rep	rep	PROPN
dpc-5316	72	4	.	.	PROPN
dpc-5316	72	5	2023;42:7–11	2023;42:7–11	PROPN
dpc-5316	72	6	.	.	PUNCT
dpc-5316	73	1	doi	doi	NOUN
dpc-5316	73	2	:	:	PUNCT
dpc-5316	73	3	10.1016	10.1016	NUM
dpc-5316	73	4	/	/	SYM
dpc-5316	73	5	j.jdcr.2023.09.024	j.jdcr.2023.09.024	PROPN
dpc-5316	73	6	.	.	PUNCT
dpc-5316	74	1	pmid	pmid	NOUN
dpc-5316	74	2	:	:	PUNCT
dpc-5316	74	3	37961078	37961078	NUM
dpc-5316	74	4	.	.	PUNCT
dpc-5316	75	1	6	6	NUM
dpc-5316	75	2	.	.	X
dpc-5316	76	1	kromer	kromer	PROPN
dpc-5316	76	2	c	c	PROPN
dpc-5316	76	3	,	,	PUNCT
dpc-5316	76	4	schön	schön	PROPN
dpc-5316	76	5	mp	mp	PROPN
dpc-5316	76	6	,	,	PUNCT
dpc-5316	76	7	mössner	mössner	PROPN
dpc-5316	76	8	r.	r.	PROPN
dpc-5316	76	9	bimekizumab	bimekizumab	PROPN
dpc-5316	76	10	in	in	ADP
dpc-5316	76	11	refractory	refractory	NOUN
dpc-5316	76	12	pityriasis	pityriasis	NOUN
dpc-5316	76	13	rubra	rubra	NOUN
dpc-5316	76	14	pilaris	pilaris	NOUN
dpc-5316	76	15	.	.	PUNCT
dpc-5316	77	1	j	j	PROPN
dpc-5316	77	2	dtsch	dtsch	PROPN
dpc-5316	77	3	dermatol	dermatol	NOUN
dpc-5316	77	4	ges	ge	NOUN
dpc-5316	77	5	.	.	PROPN
dpc-5316	77	6	2024;22(1	2024;22(1	NUM
dpc-5316	77	7	):	):	PUNCT
dpc-5316	78	1	102–104	102–104	X
dpc-5316	78	2	.	.	PUNCT
dpc-5316	78	3	doi	doi	NOUN
dpc-5316	78	4	:	:	PUNCT
dpc-5316	78	5	10.1111	10.1111	NUM
dpc-5316	78	6	/	/	SYM
dpc-5316	78	7	ddg.15252	ddg.15252	NOUN
dpc-5316	78	8	.	.	PUNCT
dpc-5316	79	1	pmid	pmid	PROPN
dpc-5316	79	2	:	:	PUNCT
dpc-5316	79	3	38066410	38066410	NUM
dpc-5316	79	4	.	.	PUNCT